From Name:
From Email:
To Name:
To Email:

Optional Message:


Ovarian cancer drug trebananib fails to improve overall survival

from Reuters

Amgen Inc. said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Statistically significant improvement in overall survival was the secondary goal of the trial. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063